v3.25.1
Acquisition of CorHepta - Schedule of Allocation of Consideration Transferred (Details) - USD ($)
3 Months Ended
Feb. 21, 2025
Mar. 31, 2025
Fair Value, Recurring [Member]    
Business Acquisition [Line Items]    
Fair value of consideration   $ 7,338,719
CorHepta Pharmaceuticals [Member]    
Business Acquisition [Line Items]    
Cash   49,633
Current liabilities   (68,208)
Fair value of consideration   7.4
CorHepta Pharmaceuticals [Member] | In Process Research and Development [Member]    
Business Acquisition [Line Items]    
Acquired IPR&D   $ 7,357,294
CorHepta Pharmaceuticals [Member] | Fair Value, Recurring [Member]    
Business Acquisition [Line Items]    
Fair value of consideration $ 7,338,719